Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 2013
[Effectiveness and adequacy of tolvaptan prescription in hospitalized patients].
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Edo Solsona Ma D, Ruiz Ramos J, Montero Hernández M, Font Noguera I, Poveda Andrés J L
Аннотация
PURPOSE: To analyse the effectiveness of the use of Tolvaptan and the adequacy of Tolvaptan prescription at a tertiary level hospital.
METHODS: Prospective observational study of Tolvaptan prescrip - tion from October of 2010 to December of 2011.
RESULTS: 30 patients (60.0% males) were included, 50.0% of which were diagnosed with heart failure and 30.0% with SIADH. Tolvaptan allowed achieving sodium levels higher than 135 mEq/L in 53.3% of the patients with a mean baseline value of 125.3±7.3 mEq/L. The median treatment duration was 5.0 days (interquartile range=3-45). A significant increase of uric acid associated to Tolvaptan treatment was observed. The prescription was in agreement to what has been established in GFT in 63.3% of the cases.
CONCLUSIONS: Tolvaptan increases sodium levels by 7.5 mEq/L, both in SIADH-associated hyponatremia and in heart failure, with an appropriate safety profile.
METHODS: Prospective observational study of Tolvaptan prescrip - tion from October of 2010 to December of 2011.
RESULTS: 30 patients (60.0% males) were included, 50.0% of which were diagnosed with heart failure and 30.0% with SIADH. Tolvaptan allowed achieving sodium levels higher than 135 mEq/L in 53.3% of the patients with a mean baseline value of 125.3±7.3 mEq/L. The median treatment duration was 5.0 days (interquartile range=3-45). A significant increase of uric acid associated to Tolvaptan treatment was observed. The prescription was in agreement to what has been established in GFT in 63.3% of the cases.
CONCLUSIONS: Tolvaptan increases sodium levels by 7.5 mEq/L, both in SIADH-associated hyponatremia and in heart failure, with an appropriate safety profile.
Предметные рубрики MeSH
Antidiuretic Hormone Receptor AntagonistsBenzazepinesDiureticsDrug CostsDrug EvaluationDrug PrescriptionsDrug Therapy, CombinationFemaleFurosemideGuideline AdherenceHeart FailureHumansHyponatremiaInappropriate ADH SyndromeInpatientsKidney Tubules, DistalLiver CirrhosisMaleNatriuresisPharmacy Service, HospitalPractice Guidelines as TopicProspective StudiesReceptors, VasopressinSodiumSpainTertiary Care CentersTolvaptanUric Acid